Figure 2.
Figure 2. PIA assay for FLT3 using plasma samples from patients treated with PKC412. Trough plasma samples from 10 patients receiving 75 mg PKC412 orally every 8 hours were used in a PIA assay for FLT3. The results are expressed as percent baseline. Each bracket marks a set of samples from the same patient, and the patient numbers correspond to the numbering used by Stone et al.4 For each patient, PIA results from day 3, day 8, and day 28 of treatment with PKC412 are shown. A day-8 sample was not available for patient 9, and a day-28 sample was not available for patient 19. For some samples,11,12 some of the columns are not visible because FLT3 phosphorylation was completely suppressed.

PIA assay for FLT3 using plasma samples from patients treated with PKC412. Trough plasma samples from 10 patients receiving 75 mg PKC412 orally every 8 hours were used in a PIA assay for FLT3. The results are expressed as percent baseline. Each bracket marks a set of samples from the same patient, and the patient numbers correspond to the numbering used by Stone et al. For each patient, PIA results from day 3, day 8, and day 28 of treatment with PKC412 are shown. A day-8 sample was not available for patient 9, and a day-28 sample was not available for patient 19. For some samples,11,12  some of the columns are not visible because FLT3 phosphorylation was completely suppressed.

Close Modal

or Create an Account

Close Modal
Close Modal